Tags

Type your tag names separated by a space and hit enter

Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.
Acta Biochim Pol. 2000; 47(1):191-9.AB

Abstract

The antigen content of plasminogen activator inhibitor-1 (PAI-1) in primary breast cancer tissue extracts may be of strong prognostic value: high levels of PAI-1 in tumors predict poor prognosis for patients. The gene encoding PAI-1 is highly polymorphic and an insertion (5G)/deletion (4G) polymorphism in the PAI-1 gene promoter (the 4G/5G polymorphism), may have functional significance in PAI-1 expression. In the present work the distribution of genotypes and frequency of alleles of the 4G/5G polymorphism in subjects with breast cancer were investigated. Tumor tissues were obtained from 100 postmenopausal women with node-negative and node-positive ductal breast carcinoma with uniform tumor size. Blood samples from age matched healthy women served as control. The 4G/5G polymorphism was determined by PCR amplification using the allele specific primers. The distribution of the genotypes of the 4G/5G polymorphism in both control and patients did not differ significantly (P > 0.05) from those predicted by the Hardy-Weinberg distribution. There were no differences in the genotype distributions and allele frequencies between node-positive and node-negative patients. The 4G/5G polymorphism may not be linked with elevated level of PAI-1 observed in breast cancer and therefore may not be associated with appearance and/or progression of breast cancer.

Authors+Show Affiliations

Błasiak J
Department of Molecular Genetics, University of Lódź, Poland. januszb@biol.uni.lodz.pl
Smolarz B
No affiliation info available

MeSH

AdultAgedAged, 80 and overBase SequenceBreast NeoplasmsDNA PrimersFemaleGenotypeHumansMiddle AgedPlasminogen Activator Inhibitor 1Polymorphism, GeneticPromoter Regions, Genetic

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10961693

Citation

Błasiak, J, and B Smolarz. "Plasminogen Activator Inhibitor-1 (PAI-1) Gene 4G/5G Promoter Polymorphism Is Not Associated With Breast Cancer." Acta Biochimica Polonica, vol. 47, no. 1, 2000, pp. 191-9.
Błasiak J, Smolarz B. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer. Acta Biochim Pol. 2000;47(1):191-9.
Błasiak, J., & Smolarz, B. (2000). Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer. Acta Biochimica Polonica, 47(1), 191-9.
Błasiak J, Smolarz B. Plasminogen Activator Inhibitor-1 (PAI-1) Gene 4G/5G Promoter Polymorphism Is Not Associated With Breast Cancer. Acta Biochim Pol. 2000;47(1):191-9. PubMed PMID: 10961693.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer. AU - Błasiak,J, AU - Smolarz,B, PY - 2000/8/29/pubmed PY - 2001/2/28/medline PY - 2000/8/29/entrez SP - 191 EP - 9 JF - Acta biochimica Polonica JO - Acta Biochim Pol VL - 47 IS - 1 N2 - The antigen content of plasminogen activator inhibitor-1 (PAI-1) in primary breast cancer tissue extracts may be of strong prognostic value: high levels of PAI-1 in tumors predict poor prognosis for patients. The gene encoding PAI-1 is highly polymorphic and an insertion (5G)/deletion (4G) polymorphism in the PAI-1 gene promoter (the 4G/5G polymorphism), may have functional significance in PAI-1 expression. In the present work the distribution of genotypes and frequency of alleles of the 4G/5G polymorphism in subjects with breast cancer were investigated. Tumor tissues were obtained from 100 postmenopausal women with node-negative and node-positive ductal breast carcinoma with uniform tumor size. Blood samples from age matched healthy women served as control. The 4G/5G polymorphism was determined by PCR amplification using the allele specific primers. The distribution of the genotypes of the 4G/5G polymorphism in both control and patients did not differ significantly (P > 0.05) from those predicted by the Hardy-Weinberg distribution. There were no differences in the genotype distributions and allele frequencies between node-positive and node-negative patients. The 4G/5G polymorphism may not be linked with elevated level of PAI-1 observed in breast cancer and therefore may not be associated with appearance and/or progression of breast cancer. SN - 0001-527X UR - https://www.unboundmedicine.com/medline/citation/10961693/Plasminogen_activator_inhibitor_1__PAI_1__gene_4G/5G_promoter_polymorphism_is_not_associated_with_breast_cancer_ DB - PRIME DP - Unbound Medicine ER -